León-de la O Dante Israel, Thorsteinsdóttir Halla, Calderón-Salinas José Víctor
Doctorate Program on Science, Technology and Society, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico.
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
PLoS One. 2018 Feb 7;13(2):e0191267. doi: 10.1371/journal.pone.0191267. eCollection 2018.
This paper analyzes the patterns of health biotechnology publications in six Latin American countries from 2001 to 2015. The countries studied were Argentina, Brazil, Chile, Colombia, Cuba and Mexico. Before our study, there were no data available on HBT development in half of the Latin-American countries we studied, i.e., Argentina, Colombia and Chile. To include these countries in a scientometric analysis of HBT provides fuller coverage of HBT development in Latin America. The scientometric study used the Web of Science database to identify health biotechnology publications. The total amount of health biotechnology production in the world during the period studied was about 400,000 papers. A total of 1.2% of these papers, were authored by the six Latin American countries in this study. The results show a significant growth in health biotechnology publications in Latin America despite some of the countries having social and political instability, fluctuations in their gross domestic expenditure in research and development or a trade embargo that limits opportunities for scientific development. The growth in the field of some of the Latin American countries studied was larger than the growth of most industrialized nations. Still, the visibility of the Latin American research (measured in the number of citations) did not reach the world average, with the exception of Colombia. The main producers of health biotechnology papers in Latin America were universities, except in Cuba were governmental institutions were the most frequent producers. The countries studied were active in international research collaboration with Colombia being the most active (64% of papers co-authored internationally), whereas Brazil was the least active (35% of papers). Still, the domestic collaboration was even more prevalent, with Chile being the most active in such collaboration (85% of papers co-authored domestically) and Argentina the least active (49% of papers). We conclude that the Latin American countries studied are increasing their health biotechnology publishing. This strategy could contribute to the development of innovations that may solve local health problems in the region.
本文分析了2001年至2015年六个拉丁美洲国家的健康生物技术出版物模式。所研究的国家有阿根廷、巴西、智利、哥伦比亚、古巴和墨西哥。在我们的研究之前,我们所研究的半数拉丁美洲国家,即阿根廷、哥伦比亚和智利,没有关于健康生物技术发展的数据。将这些国家纳入健康生物技术的科学计量分析能更全面地涵盖拉丁美洲的健康生物技术发展情况。该科学计量研究使用科学网数据库来识别健康生物技术出版物。在所研究的时期内,全球健康生物技术产出总量约为40万篇论文。其中1.2%的论文是由本研究中的六个拉丁美洲国家的作者撰写的。结果表明,尽管部分国家存在社会和政治不稳定、国内研发支出波动或限制科学发展机会的贸易禁运,但拉丁美洲的健康生物技术出版物仍显著增长。一些所研究的拉丁美洲国家在该领域的增长幅度大于大多数工业化国家。不过,除哥伦比亚外,拉丁美洲研究的影响力(以被引用次数衡量)未达到世界平均水平。拉丁美洲健康生物技术论文的主要产出者是大学,但在古巴,政府机构是最主要的产出者。所研究的国家积极开展国际研究合作,其中哥伦比亚最为活跃(64%的论文为国际合作撰写),而巴西最不活跃(35%的论文)。然而,国内合作更为普遍,智利在国内合作方面最为活跃(85%的论文为国内合作撰写),阿根廷最不活跃(49%的论文)。我们得出结论,所研究的拉丁美洲国家在增加其健康生物技术方面的出版物。这一策略可能有助于推动创新发展,从而解决该地区的局部健康问题。